Advice

following a full submission considered under the end of life and orphan equivalent process:

atezolizumab (Tecentriq®) is not recommended for use within NHSScotland.

Indication under review: As monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma after prior platinum-containing chemotherapy.

In a phase III randomised study of patients with locally advanced or metastatic urothelial carcinoma after prior platinum-containing chemotherapy, there was a small numerical increase in median overall survival for patients treated with atezolizumab compared with chemotherapy.

The submitting company did not present a sufficiently robust clinical and economic analysis to gain acceptance by SMC.

This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.

This advice replaces the second line recommendation for atezolizumab SMC No 1297/18.

Medicine details

Medicine name:
atezolizumab (Tecentriq)
SMC ID:
SMC2103
Indication:
As monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma: − after prior platinum-containing chemotherapy, or − who are considered cisplatin ineligible
Pharmaceutical company
Roche
BNF chapter
Malignant disease and immunosuppression
Submission type
Full submission
Status
Not recommended
Date advice published:
12 November 2018